The TB
Alliance, which is funded by several governments and foundations, said the new
drug combination offers promise in the fight against TB, which kills an
estimated 1.4 million people each year, mostly in Africa.
Health
experts said the new program could be particularly useful for an estimated
650,000 people around the world who suffer from multidrug-resistant TB
(MDR-TB), a number expected to rise, and could shorten treatment times.
"There
is new momentum and new hope in TB research, as shown by this and several other
novel regimen trials that will soon be launched," said Mel Spigelman,
president and chief executive of the TB Alliance.
"This
novel TB drug regimen has the potential to unlock a new and more efficient
approach to tackling TB.
"In
essence, it's a step toward erasing the distinction between TB and MDR-TB --
and in the process, dramatically shortening, simplifying, and improving
treatment," he added.
Currently,
someone with TB must take a course of drugs daily for six months, while those
with MDR-TB must take a daily injection for the first six months and a dozen or
more pills each day for 18 months or more.
Many TB
patients fail to complete treatment because they cannot tolerate the difficult
side effects of the medications or cannot adhere to the long-term treatment,
according to the TB Alliance.
This
leads to drug resistant forms of the disease, or even extensively
drug-resistant TB known as XDR-TB.
"The
current TB treatment takes too long, and all around the world, patients needlessly
suffer because today's treatment is completely inadequate," said Francis
George Apina of the Network of Men Living with HIV/AIDS in Kenya.
The TB
Alliance receives funding from the Bill & Melinda Gates Foundation, Irish
Aid, Britain's Department for International Development, the US Agency for
International Development, and the US Food and Drug Administration.
The new
regimen being tested could shorten required treatment to as little as four
months in both patients with TB and some forms of drug-resistant TB, compared
with the current six to 24 months. Costs will also be vastly reduced.
Once
known as "consumption" for the slow wasting away of terminally-ill
patients, one out of every three people is thought to be infected by the
airborne TB organism, though only a fraction go on to develop the disease.
A total
of 8.8 million people worldwide fell ill with the contagious lung disease in
2010 and around 1.4 million died, according to the World Health Organization
(WHO).
The new
trials will take place at eight sites in South Africa, Tanzania, and Brazil,
the alliance said.
Dr
Anthony Fauci, director of the US-based National Institute of Allergy and
Infectious Diseases, said he was "optimistic" on the outlook for
treating TB.
"We
have put a lot of effort over the last few years in developing new drugs
regimens and the clinical trial is a step in the right direction to trial and
get new TB drugs, particularly for those against drugs resistance," he
said.
"It's
the first time we have tried to address the multi-resistance problem with a
combination of new drugs. We tried before but not in combination," he
added.
-AFP/bz
Business & Investment Opportunities
YourVietnamExpert is a division of Saigon Business Corporation Pte Ltd, Incorporated in Singapore since 1994. As Your Business Companion, we propose a range of services in Consulting, Investment and Management, focusing three main economic sectors: International PR; Healthcare & Wellness;and Tourism & Hospitality. We also propose Higher Education, as a bridge between educational structures and industries, by supporting international programs. Sign up with twitter to get news updates with @SaigonBusinessC. Thanks.
No comments:
Post a Comment